A plain language summary of NALIRIFOX compared with nab-paclitaxel and gemcitabine for patients with metastatic pancreatic cancer (NAPOLI 3)

Zev A. Wainberg; Davide Melisi; Teresa Macarulla; Roberto Pazo Cid; Sreenivasa R. Chandana; Christelle De La Fouchardière; Andrew Dean; Igor Kiss; Woo Jin Leei; Thorsten O. Goetze; Eric Van Cutsem; A. Scott Paulson; Tanios Bekaii-Saab; Shubham Pant; Richard A. Hubner; Zhimin Xiao; Huanyu Chen; Fawzi Benzaghou; Eileen M. O’Reilly

Journal ArticleOPEN ACCESS

A plain language summary of NALIRIFOX compared with nab-paclitaxel and gemcitabine for patients with metastatic pancreatic cancer (NAPOLI 3)

Future Oncology (2025) 21(7) 765-774

DOI: 10.1080/14796694.2025.2458458

3Citations

5Readers

Cite

CITATION STYLE

APA

Wainberg, Z. A., Melisi, D., Macarulla, T., Pazo Cid, R., Chandana, S. R., De La Fouchardière, C., … O’Reilly, E. M. (2025). A plain language summary of NALIRIFOX compared with nab-paclitaxel and gemcitabine for patients with metastatic pancreatic cancer (NAPOLI 3). Future Oncology, 21(7), 765–774. https://doi.org/10.1080/14796694.2025.2458458

A plain language summary of NALIRIFOX compared with nab-paclitaxel and gemcitabine for patients with metastatic pancreatic cancer (NAPOLI 3)

Cite

Register to see more suggestions